Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eflornithine, (S)-. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 known ✓ | P11926 | 2/20 | 0.92 |
| ▸ | BLM | P54132 | 3/20 | 0.96 |
| ▸ | LMNA | P02545 | 3/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.96 |
| ▸ | MAPT | P10636 | 1/20 | 0.96 |
| ▸ | RAB9A | P51151 | 1/20 | 0.96 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.96 |
| ▸ | ARG1 | P05089 | 3/20 | 0.59 |
| ▸ | ARG2 | P78540 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eflornithine SCHEMBL4510 | 1.00 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| D-Eflornithine SCHEMBL3238104 | 1.00 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL4809264 | 1.00 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL5051665 | 1.00 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL1397750 | 1.00 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| D-Eflornithine SCHEMBL7208883 | 0.98 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL6779168 | 0.98 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine, (S)- SCHEMBL6779172 | 0.98 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL3244711 | 0.98 | ODC1 (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine, (S)- SCHEMBL1322403 | 0.98 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421058-B1 | PROCESSES FOR THE PRODUCTION OF ALPHA-DIFLUOROMETHYL ORNITHINE (DFMO) | SKINMEDICA INC (US) | 2010-05-05 | — | — | EP | claimed |
| US-6743822-B2 | APPLYING TO AREA OF SKIN A DERMATOLOGICALLY ACCEPTABLE COMPOSITION COMPRISING ALPHA -DIFLUOROMETHYLORNITHINE IN AN AMOUNT EFFECTIVE TO REDUCE HAIR GROWTH | THE GILLETTE COMPANY | 2004-06-01 | — | — | US | claimed |
| US-6730809-B2 | FORMED VIA CHEMICAL REDUCTION AND HYDROLYSIS WITH MINIMAL USE OF HALOGENATED SOLVENTS; COMPRISES USE OF INTERMEDIATES SUCH AS ETHYL 2-BENZYLIDENEAMINO-2-DIFLUOROMETHYL-4-CYANOBUTANOATE | WOMEN FIRST HEALTHCARE, INC. | 2004-05-04 | — | — | US | claimed |
| US-20030083384-A1 | Processes for the production of alpha-difluoromethyl ornithine (DFMO) | BRISTOL-MYERS SQUIBB COMPANY TO WOMEN FIRST HEALTHCARE, INC. | 2003-05-01 | — | — | US | claimed |
| US-6462229-B1 | IT HAS BEEN FOUND THAT (.+-.)-.ALPHA.-DIFLUOROMETHYLORNITHINE CAN BE CLEAVED USING THE COMMERCIALLY OBTAINABLE (-)-O,O'-DI-P-TOLUOYL-L-TARTARIC ACID | LONZA LTD. (CH) | 2002-10-08 | — | — | US | claimed |
| EP-4294362-A1 | AN EFLORNITHINE COMPOSITION FOR INHIBITING HAIR GROWTH | Navin Saxena Research and Technology Private Limited (IN) | 2023-12-27 | — | — | EP | disclosed |
| WO-2022175985-A1 | AN EFLORNITHINE COMPOSITION FOR INHIBITING HAIR GROWTH | NAVIN SAXENA RESEARCH AND TECHNOLOGY PRIVATE LIMITED (IN) | 2022-08-25 | — | — | WO | disclosed |
| US-20140371165-A1 | Identification of NSC23925 Isomers to Reverse Multidrug Resistance in Human Cancers | THE GENERAL HOSPITAL CORPORATION (US) | 2014-12-18 | — | — | US | disclosed |
| US-8802702-B2 | Compounds for reducing drug resistance and uses thereof | THE GENERAL HOSPITAL CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| WO-2013126664-A1 | IDENTIFICATION OF NSC23925 ISOMERS TO REVERSE MULTIDRUG RESISTANCE IN HUMAN CANCERS | THE GENERAL HOSPITAL CORPORATION (US) | 2013-08-29 | — | — | WO | disclosed |
| US-20120035126-A1 | Compounds For Reducing Drug Resistance And Uses Thereof | THE GENERAL HOSPITAL CORPORATION | 2012-02-09 | — | — | US | disclosed |
| WO-2010083385-A2 | COMPOUNDS FOR REDUCING DRUG RESISTANCE AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2010-07-22 | — | — | WO | disclosed |
| US-7345196-B1 | Convenient process of manufacture for difluoromethylornithine and related compounds | SABINSA CORPORATION (US) | 2008-03-18 | — | — | US | disclosed |
| US-6998502-B1 | Convenient process of manufacture for difluoromethylornithine and related compounds | SABINSA CORPORATION (US) | 2006-02-14 | — | — | US | disclosed |
| US-6462229-B1 | IT HAS BEEN FOUND THAT (.+-.)-.ALPHA.-DIFLUOROMETHYLORNITHINE CAN BE CLEAVED USING THE COMMERCIALLY OBTAINABLE (-)-O,O'-DI-P-TOLUOYL-L-TARTARIC ACID | LONZA LTD. (CH) | 2002-10-08 | — | — | US | disclosed |
| US-6462229-B1 | IT HAS BEEN FOUND THAT (.+-.)-.ALPHA.-DIFLUOROMETHYLORNITHINE CAN BE CLEAVED USING THE COMMERCIALLY OBTAINABLE (-)-O,O'-DI-P-TOLUOYL-L-TARTARIC ACID | LONZA LTD. (CH) | 2002-10-08 | — | — | US | disclosed |
| US-6462229-B1 | IT HAS BEEN FOUND THAT (.+-.)-.ALPHA.-DIFLUOROMETHYLORNITHINE CAN BE CLEAVED USING THE COMMERCIALLY OBTAINABLE (-)-O,O'-DI-P-TOLUOYL-L-TARTARIC ACID | LONZA LTD. (CH) | 2002-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083384-A1 | Processes for the production of alpha-difluoromethyl ornithine (DFMO) | ODC1, OTC, OAT | ODC1 1/4885BLM 3564/4885LMNA 4162/4885 |
| US-20120035126-A1 | Compounds For Reducing Drug Resistance And Uses Thereof | ABCC1, SLC11A2, NQO1 | ODC1 1558/4885BLM 808/4885LMNA 1646/4885 |
| US-20140371165-A1 | Identification of NSC23925 Isomers to Reverse Multidrug Resistance in Human Cancers | ABCC1, MCL1, ABCB1 | ODC1 2380/4885BLM 846/4885LMNA 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.